Product Information
GVOKE PFS 1-PK 1 MG/0.2 ML SYR is a brand product labeled by Xeris Pharmaceuticals, Inc., priced at $1600.9565 per ML under NDC 72065013111. Its NADAC has been published 333 times since May 20, 2020.
FDA first approved this application on Sep 10, 2019.
Strength
1 mg/.2mL
Manufacturer
Xeris Pharmaceuticals, Inc.NDC
72065013111
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
GLUCAGONApproval Type
New Drug (NDA)
FDA Application
NDA212097FDA Approved
9/10/2019
On Market Since
9/10/2019
Pharmacological Classes
Price Statistics
The NADAC for GVOKE PFS 1-PK 1 MG/0.2 ML SYR has been published 333 times since May 20, 2020, and over the history we have for it it has risen 19.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1600.9565 per ML |
|---|---|
| All-time high | $1604.3171 (Jun 10, 2026) |
| All-time low | $1340.0286 (May 20, 2020) |
| 52-week high | $1604.3171 |
| 52-week low | $1557.3479 |
| Median price | $1468.9945 |
| Average price | $1466.5933 |
| Largest weekly change | +3.0% (Feb 15, 2023) |
| Weeks tracked | 333 |
| Tracking since | May 20, 2020 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Xeris Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
glucagon injection, solution market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antihypoglycemic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GVOKE PFS 1-PK 1 MG/0.2 ML SYR?
The current National Average Drug Acquisition Cost (NADAC) for GVOKE PFS 1-PK 1 MG/0.2 ML SYR, manufactured by Xeris Pharmaceuticals, Inc., is $1600.9565 per ML (NDC 72065013111), effective Sep 30, 2026.
How has the price of GVOKE PFS 1-PK 1 MG/0.2 ML SYR changed over time?
Over the history we have for it, the NADAC for GVOKE PFS 1-PK 1 MG/0.2 ML SYR has risen 19.5%. It has been tracked across 333 weekly CMS publications since May 20, 2020.
What are the highest and lowest recorded NADAC prices for GVOKE PFS 1-PK 1 MG/0.2 ML SYR?
Since May 20, 2020, the NADAC for GVOKE PFS 1-PK 1 MG/0.2 ML SYR has ranged from a low of $1340.0286 (May 20, 2020) to a high of $1604.3171 (Jun 10, 2026), with a median of $1468.9945 per ML.
Are there cheaper alternatives to GVOKE PFS 1-PK 1 MG/0.2 ML SYR?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GVOKE HYPOPEN 2-PK 1 MG/0.2 ML, is $1596.1935 per ML — about 0% below GVOKE PFS 1-PK 1 MG/0.2 ML SYR.
Who manufactures GVOKE PFS 1-PK 1 MG/0.2 ML SYR?
GVOKE PFS 1-PK 1 MG/0.2 ML SYR (NDC 72065013111) is labeled by Xeris Pharmaceuticals, Inc., and CMS classifies it as a brand product.